Article Text

Download PDFPDF
Farber’s disease without central nervous system involvement: bone-marrow transplantation provides a promising new approach
  1. K Ehlert1,
  2. J Roth2,
  3. M Frosch2,
  4. N Fehse3,
  5. N Zander3,
  6. J Vormoor1
  1. 1Department of Pediatric Hematology and Oncology, University Hospital Muenster, Muenster, UK
  2. 2Department of General Pediatrics, University Hospital Muenster, Muenster, UK
  3. 3University Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Germany
  1. Correspondence to:
    J Vormoor
    Newcastle University, Northern Institute for Cancer Research, Framlington Place, Newcastle upon Tyne, PO Box Münster 48149, UK; h.j.vormoor{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Farber’s disease is a lysosomal storage disorder caused by acid ceramidase deficiency.1 The main symptoms in patients without central nervous system (CNS) involvement (type 2/3), are caused by leucocyte dysregulation,2 with impaired apoptosis and signal transduction caused by intracellularly accumulated ceramide, leading to the inflammatory component of this disorder, with swelling of joints, granuloma formation, contractures and inflammatory airway involvement.6 Current treatment focuses on pain management, physical treatment, surgical correction of contractures and treatment with anti-inflammatory drugs. In rheumatoid disorders such as juvenile rheumatoid arthritis, immunosuppression or autologous haematopoietic stem cell transplantation (HSCT) can afford a substantial benefit, as treatment is based on suppression of abundant inflammatory responses by …

View Full Text


  • Competing interests: None.